The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial - OCEAN
Atrial FibrillationAtrial fibrillation is an abnormal heart rhythm in which can increase the risk of developing clots in the heart which can then break off and travel to the brain and cause a stroke.
Catheter ablation is a procedure which is used to restore the regular rhythm of the heart; however even when this treatment is successful, patients still may have an increased risk of having a stroke compared to people who have never had atrial fibrillation.
Two types of medication are presently prescribed to patients following their catheter ablation (even if it appears to have been successful in eliminating atrial fibrillation): an antiplatelet (such as aspirin), or an anticoagulant (also known as a blood thinner). This study is being done in order to find out which type of medication works best for preventing strokes in people who have had a successful catheter ablation.
null
Participation Requirements
-
Sex:
Male, Female, Intersex -
Eligible Ages:
18 to 85
Participation Criteria
Inclusion Criteria:
->18 years old
-At least 1 year following successful catheter ablation for AF (Holter monitor reports required)
-Acceptable stroke risk score (determined by physician)
Exclusion Criteria:
-Unable to use blood thinners
-Kidney disease
-Metal heart valve
-Unable to have MRI
-Stroke within 1 year
Study Location
Victoria Cardiac Arrhythmia Trials Inc.
Victoria Cardiac Arrhythmia Trials Inc.Victoria, British Columbia
Canada
Contact Study Team
St. Mary's General Hospital
St. Mary's General HospitalKitchener, Ontario
Canada
Contact Study Team
Scarborough Health Network- Rougevalley
Scarborough Health Network- RougevalleyToronto, Ontario
Canada
Contact Study Team
Centre Hospitalier de L'Universite de Montreal (CHUM)
Centre Hospitalier de L'Universite de Montreal (CHUM)Montreal, Quebec
Canada
Contact Study Team
Institut Universitarie de Cardiologie et de Pneumologie de Quebec
Institut Universitarie de Cardiologie et de Pneumologie de QuebecQuébec, Quebec
Canada
Contact Study Team
Royal Columbian/Fraser Clinical Trials
Royal Columbian/Fraser Clinical TrialsNew Westminster, British Columbia
Canada
Contact Study Team
Hamilton Health Sciences Centre
Hamilton Health Sciences CentreHamilton, Ontario
Canada
Contact Study Team
Southlake Regional Health Centre
Southlake Regional Health CentreNewmarket, Ontario
Canada
Contact Study Team
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences CentreToronto, Ontario
Canada
Contact Study Team
McGill University Health Centre
McGill University Health CentreMontreal, Quebec
Canada
Contact Study Team
St. Paul's Hospital
St. Paul's HospitalVancouver, British Columbia
Canada
Contact Study Team
Kingston General Hospital
Kingston General HospitalKingston, Ontario
Canada
Contact Study Team
University of Ottawa Heart Institute
University of Ottawa Heart InstituteOttawa, Ontario
Canada
Contact Study Team
Sherbrooke- Grandby site
Sherbrooke- Grandby siteGranby, Quebec
Canada
Contact Study Team
Montreal Health Institute
Montreal Health InstituteMontreal, Quebec
Canada
Contact Study Team
Foothills Medical Centre
Foothills Medical CentreCalgary, Alberta
Canada
Contact Study Team
Queen Elizabeth II Health Sciences Centre
Queen Elizabeth II Health Sciences CentreHalifax, Nova Scotia
Canada
Contact Study Team
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contact Study Team
St. Michael's Hospital
St. Michael's HospitalToronto, Ontario
Canada
Contact Study Team
Hôpital du Sacré-Coeur de Montreal
Hôpital du Sacré-Coeur de MontrealMontreal, Quebec
Canada
Contact Study Team
Centre Hospitalier Universitaire de Sherbrooke
Centre Hospitalier Universitaire de SherbrookeSherbrooke, Quebec
Canada
Contact Study Team
University of Calgary
University of CalgaryCalgary, Alberta
Canada
Contact Study Team
- Study Sponsored By
- Ottawa Heart Institute Research Corporation
- Participants Required
- More Information
- Study ID:
NCT02168829